CNTX
NASDAQContext Therapeutics Inc.
Price$0.61-0.01 (-1.62%)
01:30 PM07:45 PM
News · 26 weeks43-80%
2026-01-252026-07-19
Mix2490d
- Other9(38%)
- SEC Filings7(29%)
- Insider6(25%)
- Earnings2(8%)
Latest news
25 items- PRContext Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context. The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted to a new employee on their hire date (July 7, 2026) with an exe
- PRContext Therapeutics Added to Russell 2000® and Russell 3000® IndexesPHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced that the Company was added to the small-cap Russell 2000® and the broad-market Russell 3000® Indexes, effective at the close of U.S. equity markets on June 26, 2026. The Russell 3000® Index measures the performance of the largest 3,000 publicly traded U.S. companies, representing approximately 98% of the investable U.S. equity market. The Russell 2000® Index is a subset of the Russell 3000® Index and serves as the leading benchmark for U.S. s
- INSIDERSEC Form 4 filed by Director Pasternak Andy4 - Context Therapeutics Inc. (0001842952) (Issuer)
- INSIDERSEC Form 4 filed by Director Stacey Jennifer Evans4 - Context Therapeutics Inc. (0001842952) (Issuer)
- INSIDERSEC Form 4 filed by Director West Linda4 - Context Therapeutics Inc. (0001842952) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith Karen L.4 - Context Therapeutics Inc. (0001842952) (Issuer)
- INSIDERSEC Form 4 filed by Director Walker Luke Nathaniel4 - Context Therapeutics Inc. (0001842952) (Issuer)
- INSIDERSEC Form 4 filed by Director Kantoff Philip W.4 - Context Therapeutics Inc. (0001842952) (Issuer)
- SECContext Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Context Therapeutics Inc. (0001842952) (Filer)
- SECContext Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Context Therapeutics Inc. (0001842952) (Filer)
- PRContext Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-7629% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer ("PROC") who progressed on a median of 7 prior lines of therapy Cytokine Release Syndrome ("CRS") in PROC limited to Grade 1 in 11% of patients Pharmacokinetic ("PK") profile supports exploration of Q3W dosing in 2H 2026 CTIM-76 has been granted FDA Fast Track Designation in PROC Company to host conference call on Monday, June 15 at 8:00 a.m. ET PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today a
- PRContext Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context. The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted to a new employee on their hire date (June 8, 2026) with an exe
- PRContext Therapeutics to Present at the Jefferies Global Healthcare ConferencePHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its presentation at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 7:35 a.m. ET. A live webcast of the presentation will be available on the News and Events section of the Company's website at https://ir.contexttherapeutics.com. Replays will be available on the website for 90 days. For additional information or to request a meeting with members of Context's management team during these events, please contact your
- SECContext Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Context Therapeutics Inc. (0001842952) (Filer)
- PRContext Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced the amendment of the Company's exclusive license agreement, dated September 23, 2024, with BioAtla, Inc. (NASDAQ:BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company's Nectin-4 x CD3 T cel
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Context Therapeutics Inc.SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)
- SECSEC Form SCHEDULE 13G filed by Context Therapeutics Inc.SCHEDULE 13G - Context Therapeutics Inc. (0001842952) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Context Therapeutics Inc.SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Context Therapeutics Inc.SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)
- PRContext Therapeutics Reports First Quarter 2026 Operating and Financial ResultsPhase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202 (Nectin-4 x CD3) trial expected in third quarter of 2026 Cash and cash equivalents of $54.5 million as of March 31, 2026 expected to fund operations into mid-2027 PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2026, and reported on
- SECSEC Form 10-Q filed by Context Therapeutics Inc.10-Q - Context Therapeutics Inc. (0001842952) (Filer)
- SECContext Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Context Therapeutics Inc. (0001842952) (Filer)
- SECSEC Form DEFA14A filed by Context Therapeutics Inc.DEFA14A - Context Therapeutics Inc. (0001842952) (Filer)
- SECSEC Form DEF 14A filed by Context Therapeutics Inc.DEF 14A - Context Therapeutics Inc. (0001842952) (Filer)
- SECSEC Form PRE 14A filed by Context Therapeutics Inc.PRE 14A - Context Therapeutics Inc. (0001842952) (Filer)
CNTX FAQ
6 questionsWhere does CNTX stock trade?
Context Therapeutics Inc. (CNTX) is listed on NASDAQ.What sector and industry is CNTX in?
Context Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Context Therapeutics Inc. go public?
Context Therapeutics Inc. (CNTX) completed its IPO in 2021.What are analysts saying about CNTX?
Context Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $500.00 price target on 2025-09-18. Recent price targets range from $400.00 to $1000.00.What companies are similar to CNTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CNTX side-by-side with any of them on Quantisnow.How can I track CNTX on Quantisnow?
Quantisnow aggregates Context Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CNTX to receive live email and push alerts on every new disclosure.